Skip to main content
SpringerLink
Log in

Individualisierte Therapie mit Stammzellen

Individualized stem cell therapy

  • Schwerpunkt
  • Published:
Herz Aims and scope Submit manuscript

Zusammenfassung

Stammzellen wird ein großes Potenzial in der regenerativen Medizin eingeräumt. Aufgrund ihrer Fähigkeit, sich unbegrenzt zu vermehren und gleichzeitig auf definierte Differenzierungsreize anzusprechen, finden pluripotente Stammzellen eine besondere Berücksichtigung. Herzmuskelzellen können heute in großer Menge aus pluripotenten Stammzellen gewonnen werden und dienen als Ausgangsmaterial sowohl für die Simulation von Herzerkrankungen in der Kulturschale („patient in a dish“) als auch für die zellbasierte Herzreparatur. Auf dem Boden der rasanten biotechnologischen Entwicklungen der letzten Jahre befinden wir uns heute in der Phase der Translation dieser Konzepte in die klinische Anwendung.

Abstract

Stem cells are attributed with having a great potential in regenerative medicine. Pluripotent stem cells are particularly interesting because they can be multiplied indefinitely and also differentiated under defined conditions. Currently, cardiomyocytes can be differentiated very effectively from pluripotent stem cells, making the former an attractive starting material for cardiac disease modeling in a culture dish (patient in a dish) and cell based-therapy in heart failure. The rapid biotechnological advances made in recent years now enable these concepts to be translated into clinical applications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Go AS, Mozaffarian D, Roger VL et al (2014) Heart disease and stroke statistics – 2014 update: a report from the American Heart Association. Circulation 129:e28–e292

    Article  PubMed  Google Scholar 

  2. Lund LH, Edwards LB, Kucheryavaya AY et al (2013) The Registry of the International Society for Heart and Lung Transplantation: thirtieth official adult heart transplant report – 2013; focus theme: age. J Heart Lung Transplant 32:951–964

    Article  PubMed  Google Scholar 

  3. Bernhardt AM, Rahmel A, Reichenspurner H (2013) The unsolved problem of organ allocation in times of organ shortage: the German solution? J Heart Lung Transplant 32:1049–1051

    Article  PubMed  Google Scholar 

  4. Rosell R, Bivona TG, Karachaliou N (2013) Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 382:720–731

    Article  PubMed  CAS  Google Scholar 

  5. Bick AG, Flannick J, Ito K et al (2012) Burden of rare sarcomere gene variants in the Framingham and Jackson Heart Study cohorts. Am J Hum Genet 91:513–519

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  6. Thomson JA, Itskovitz-Eldor J, Shapiro SS et al (1998) Embryonic stem cell lines derived from human blastocysts. Science 282:1145–1147

    Article  PubMed  CAS  Google Scholar 

  7. Takahashi K, Tanabe K, Ohnuki M et al (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861–872

    Article  PubMed  CAS  Google Scholar 

  8. Revazova ES, Turovets NA, Kochetkova OD et al (2007) Patient-specific stem cell lines derived from human parthenogenetic blastocysts. Cloning Stem Cells 9:432–449

    Article  PubMed  CAS  Google Scholar 

  9. Pittenger MF, Mackay AM, Beck SC et al (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284:143–147

    Article  PubMed  CAS  Google Scholar 

  10. Gnecchi M, He H, Liang OD et al (2005) Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 11:367–368

    Article  PubMed  CAS  Google Scholar 

  11. Burridge PW, Keller G, Gold JD, Wu JC (2012) Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell 10:16–28

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  12. Carlson C, Koonce C, Aoyama N et al (2013) Phenotypic screening with human iPS cell-derived cardiomyocytes: HTS-compatible assays for interrogating cardiac hypertrophy. J Biomol Screen 18:1203–1211

    Article  PubMed  Google Scholar 

  13. Schaaf S, Shibamiya A, Mewe M et al (2011) Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. PLoS One 6:e26397

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  14. Tiburcy M, Zimmermann WH (2014) Modeling myocardial growth and hypertrophy in engineered heart muscle. Trends Cardiovasc Med 24:7–13

    Article  PubMed  CAS  Google Scholar 

  15. Gepstein L (2002) Derivation and potential applications of human embryonic stem cells. Circ Res 91:866–876

    Article  PubMed  CAS  Google Scholar 

  16. Zimmermann WH, Melnychenko I, Wasmeier G et al (2006) Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat Med 12:452–458

    Article  PubMed  CAS  Google Scholar 

  17. Didie M, Christalla P, Rubart M et al (2013) Parthenogenetic stem cells for tissue-engineered heart repair. J Clin Invest 123:1285–1298

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  18. Soong PL, Tiburcy M, Zimmermann WH (2012) Cardiac differentiation of human embryonic stem cells and their assembly into engineered heart muscle. Curr Protoc Cell Biol, Chapter 23:Unit23.8

    Google Scholar 

  19. Naito H, Melnychenko I, Didie M et al (2006) Optimizing engineered heart tissue for therapeutic applications as surrogate heart muscle. Circulation 114:I72–I78

    Article  PubMed  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. W.-H. Zimmermann gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Institute for Pharmacology, University Medical Center, Georg-August-University, Robert-Koch-Str. 40, 37075, Göttingen, Deutschland

    W.-H. Zimmermann

Authors
  1. W.-H. Zimmermann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W.-H. Zimmermann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zimmermann, WH. Individualisierte Therapie mit Stammzellen. Herz 39, 201–205 (2014). https://doi.org/10.1007/s00059-014-4073-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00059-014-4073-6

Schlüsselwörter

Keywords

Search

Navigation